Using Pharmacokinetic and Viral Kinetic Modeling To Estimate the Antiviral Effectiveness of Telaprevir, Boceprevir, and Pegylated Interferon during Triple Therapy in Treatment-Experienced Hepatitis C Virus-Infected Cirrhotic Patients.: Effectiveness of triple therapy in cirrhotic patients

Abstract : Triple therapy combining a protease inhibitor (PI) (telaprevir or boceprevir), pegylated interferon (PEG-IFN), and ribavirin (RBV) has dramatically increased the chance of eradicating hepatitis C virus (HCV). However, the efficacy of this treatment remains suboptimal in cirrhotic treatment-experienced patients. Here, we aimed to better understand the origin of this impaired response by estimating the antiviral effectiveness of each drug. Fifteen HCV genotype 1-infected patients with compensated cirrhosis, who were nonresponders to prior PEG-IFN/RBV therapy, were enrolled in a nonrandomized study. HCV RNA and concentrations of PIs, PEG-IFN, and RBV were frequently assessed in the first 12 weeks of treatment and were analyzed using a pharmacokinetic/viral kinetic model. The two PIs achieved similar levels of molar concentrations (P = 0.5), but there was a significant difference in the 50% effective concentrations (EC50) (P = 0.008), leading to greater effectiveness for telaprevir than for boceprevir in blocking viral production (99.8% versus 99.0%, respectively, P = 0.002). In all patients, the antiviral effectiveness of PEG-IFN was modest (43.4%), and there was no significant contribution of RBV exposure to the total antiviral effectiveness. The second phase of viral decline, which is attributed to the loss rate of infected cells, was slow (0.19 day(-1)) and was higher in patients who subsequently eradicated HCV (P = 0.03). The two PIs achieved high levels of antiviral effectiveness. However, the suboptimal antiviral effectiveness of PEG-IFN/RBV and the low loss of infected cells suggest that a longer treatment duration might be needed in cirrhotic treatment-experienced patients and that a future IFN-free regimen may be particularly beneficial in these patients.
Type de document :
Article dans une revue
Antimicrobial Agents and Chemotherapy, American Society for Microbiology, 2014, 58 (9), pp.5332-41. 〈10.1128/AAC.02611-14〉
Liste complète des métadonnées

Littérature citée [7 références]  Voir  Masquer  Télécharger

http://www.hal.inserm.fr/inserm-01059165
Contributeur : Cédric Laouénan <>
Soumis le : vendredi 29 août 2014 - 14:34:25
Dernière modification le : mercredi 5 septembre 2018 - 15:32:02
Document(s) archivé(s) le : dimanche 30 novembre 2014 - 10:45:28

Fichier

MODCUPIC_AAC_review_70434_2_me...
Fichiers produits par l'(les) auteur(s)

Identifiants

Citation

Cédric Laouénan, Patrick Marcellin, Martine Lapalus, Feryel Khelifa-Mouri, Nathalie Boyer, et al.. Using Pharmacokinetic and Viral Kinetic Modeling To Estimate the Antiviral Effectiveness of Telaprevir, Boceprevir, and Pegylated Interferon during Triple Therapy in Treatment-Experienced Hepatitis C Virus-Infected Cirrhotic Patients.: Effectiveness of triple therapy in cirrhotic patients. Antimicrobial Agents and Chemotherapy, American Society for Microbiology, 2014, 58 (9), pp.5332-41. 〈10.1128/AAC.02611-14〉. 〈inserm-01059165〉

Partager

Métriques

Consultations de la notice

968

Téléchargements de fichiers

294